GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

China Health Management CNHC · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 23 Oct 2026, in USD

At a glance

Figures in USD, from our data supplier.

FY2026

Revenue

$40,038

FY2020FY2026

Net income

$1,367

FY2020FY2026

Free cash flow

$112,620

FY2020FY2026

Shareholders' equity

−$316,081

FY2020FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Revenue$40,038$52,651$49,593$27,402———
Gross profit$37,629$49,440$46,283$27,402———
Operating income$22,478$7,540−$40,820$8,890−$8,950−$10,280−$770
Net income$1,367−$7,934−$78,278−$872−$8,949−$10,283−$769
Diluted earnings per share0.00-0.00-0.00-0.00-0.00-0.00-0.00

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Total assets$942,318$941,796$1.2m$1.2m———
Cash and short-term investments$14,542$11,131$13,640$12,765———
Total liabilities$1.2m$1.1m$1.4m$1.3m$19,232——
Debt$490,645$465,821$662,166$717,822$16,989——
Shareholders' equity−$316,081−$203,355−$163,734−$34,900−$19,232—$81,146
Shares outstanding81m81m81m81m81m81m81m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations$112,624−$33,566$42,137$34,492−$7,749—−$769
Capital spending−$4−$4−$3————
Free cash flow$112,620−$33,570$42,134$34,492−$7,749—−$769

Latest quarters

By quarter end

Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024
Revenue$13,911$13,530$12,597$13,779$11,980$12,253$14,639$12,894
Gross profit$13,108$12,727$11,794——$8,121—$12,848
Operating income$9,663$5,444$7,371$9,299$1,664−$9,614$6,191$12,151
Net income$4,928−$7,320$3,759$19,937$829−$31,857$3,157$26,207
Diluted earnings per share0.00-0.000.000.000.00-0.000.000.00
Total assets$942,318$941,999$947,527$941,796$952,362$958,829$1.4m$1.2m
Cash and short-term investments$14,542$14,956$17,217$11,131$21,402$27,360$15,277$13,640
Debt$490,645$502,845$485,822$465,821$490,889$491,572$734,994$662,166
Shareholders' equity−$313,453−$324,728−$261,202−$203,355−$261,811−$242,441−$201,146−$163,734

Growth per year

Compound annual rate

3 years5 years10 years
Revenue13.5%—-20.6%
Operating income36.2%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin93.9%94.7%——
Operating margin32.4%-1.1%——
Net margin-7.1%-50.5%——

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings243.4-1.5-0.1-2.6-0.0-0.0-0.2
Price to sales8.30.20.10.1———

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return161%139%374%102%77%325%665%83003%1540%1100%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 30 Oct 2006
  • 100-to-1 reverse split · 4 Aug 2006

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.